<?xml version="1.0" ?>
<text author="José das Neves" dateCollected="2019-11-03" id="autogum_academic_doc482" shortTile="novel-approaches" sourceURL="https://www.mdpi.com/1999-4923/11/11/554/htm" speakerCount="0" speakerList="none" title="Novel Approaches for the Delivery of Anti-HIV Drugs — What Is New?" type="academic">
<p>
<s type="decl">
HIV/AIDS	NNS	HIV/AIDS
continues	VBZ	continue
to	TO	to
be	VB	be
one	CD	one
of	IN	of
the	DT	the
most	RBS	most
challenging	VBG	challenge
individual	JJ	individual
and	CC	and
public	JJ	public
health	NN	health
concerns	NNS	concern
of	IN	of
our	PRP$	our
days	NNS	day
.	.	.
</s>
<s type="decl">
According	VBG	accord
to	TO	to
the	DT	the
latest	JJS	late
UNAIDS	NNP	UNAIDS
data	NNS	datum
,	,	,
in	IN	in
2018	CD	@card@
,	,	,
roughly	RB	roughly
37.9	CD	@card@
million	CD	million
individuals	NNS	individual
were	VBD	be
infected	VBN	infect
with	IN	with
HIV	NNP	HIV
globally	RB	globally
,	,	,
while	IN	while
around	RB	around
770,000	CD	@card@
people	NNS	people
died	VBD	die
of	IN	of
AIDS-related	JJ	AIDS-related
illness	NN	illness
.	.	.
</s>
<s type="decl">
During	IN	during
that	DT	that
same	JJ	same
year	NN	year
,	,	,
an	DT	an
estimated	VBN	estimate
1.7	CD	@card@
million	CD	million
new	JJ	new
infections	NNS	infection
occurred	VBD	occur
,	,	,
mainly	RB	mainly
due	JJ	due
to	TO	to
unprotected	JJ	unprotected
sexual	JJ	sexual
intercourse	NN	intercourse
.	.	.
</s>
<s type="decl">
Investment	NN	Investment
in	IN	in
the	DT	the
field	NN	field
has	VBZ	have
been	VBN	be
considerable	JJ	considerable
,	,	,
but	CC	but
a	DT	a
cure	NN	cure
to	TO	to
the	DT	the
infection	NN	infection
remains	VBZ	remain
elusive	JJ	elusive
.	.	.
</s>
<s type="decl">
Nonetheless	RB	Nonetheless
,	,	,
tremendous	JJ	tremendous
advances	NNS	advance
have	VBP	have
been	VBN	be
made	VBN	make
over	IN	over
the	DT	the
last	JJ	last
36	CD	@card@
years	NNS	year
since	IN	since
HIV-1	NNP	HIV-1
was	VBD	be
identified	VBN	identify
,	,	,
namely	RB	namely
in	IN	in
prevention	NN	prevention
,	,	,
diagnostics	NNS	diagnostics
,	,	,
and	CC	and
treatment	NN	treatment
.	.	.
</s>
<s type="decl">
The	DT	the
development	NN	development
of	IN	of
antiretroviral	NN	antiretroviral
drugs	NNS	drug
and	CC	and
the	DT	the
introduction	NN	introduction
of	IN	of
highly	RB	highly
active	JJ	active
antiretroviral	NN	antiretroviral
therapy	NN	therapy
(	-LRB-	(
HAART	NNP	HAART
)	-RRB-	)
in	IN	in
the	DT	the
mid-1990s	NNS	mid-1990s
—	:	—
currently	RB	currently
referred	VBN	refer
to	TO	to
as	IN	as
combination	NN	combination
antiretroviral	NN	antiretroviral
therapy	NN	therapy
(	-LRB-	(
cART	NN	cART
)	-RRB-	)
—	:	—
led	VBD	lead
to	TO	to
a	DT	a
dramatic	JJ	dramatic
shift	NN	shift
of	IN	of
AIDS	NNP	AIDS
from	IN	from
a	DT	a
fatal	JJ	fatal
disease	NN	disease
into	IN	into
a	DT	a
chronic	JJ	chronic
and	CC	and
often	RB	often
stable	JJ	stable
medical	JJ	medical
condition	NN	condition
.	.	.
</s>
<s type="decl">
In	IN	in
fact	NN	fact
,	,	,
cART	NN	cART
contributed	VBD	contribute
decisively	RB	decisively
to	TO	to
a	DT	a
steady	JJ	steady
decrease	NN	decrease
in	IN	in
the	DT	the
number	NN	number
of	IN	of
HIV-related	JJ	HIV-related
deaths	NNS	death
since	IN	since
the	DT	the
first	JJ	first
years	NNS	year
of	IN	of
the	DT	the
new	JJ	new
millennium	NN	millennium
.	.	.
</s>
<s type="decl">
Antiretroviral	NN	antiretroviral
drugs	NNS	drug
have	VBP	have
also	RB	also
been	VBN	be
found	VBN	find
useful	JJ	useful
in	IN	in
the	DT	the
prevention	NN	prevention
field	NN	field
,	,	,
particularly	RB	particularly
in	IN	in
post-exposure	JJ	post-exposure
prophylaxis	NN	prophylaxis
or	CC	or
mother-to-child	JJ	mother-to-child
transmission	NN	transmission
.	.	.
</s>
<s type="decl">
Treatment	NN	Treatment
as	IN	as
prevention	NN	prevention
and	CC	and
pre-exposure	NN	pre-exposure
prophylaxis	NN	prophylaxis
(	-LRB-	(
PrEP	NNP	PrEP
)	-RRB-	)
have	VBP	have
further	RBR	far
contributed	VBN	contribute
to	TO	to
the	DT	the
reduction	NN	reduction
of	IN	of
sexually	RB	sexually
transmitted	VBN	transmitted
HIV	NN	HIV
infections	NNS	infection
.	.	.
</s>
<s type="sub">
Long-lasting	VBG	Long-lasting
injectable	NN	injectable
products	NNS	product
and	CC	and
antiretroviral-based	JJ	antiretroviral-based
microbicides	NNS	microbicide
that	WDT	that
are	VBP	be
currently	RB	currently
in	IN	in
late	JJ	late
stages	NNS	stage
of	IN	of
clinical	JJ	clinical
development	NN	development
or	CC	or
regulatory	JJ	regulatory
approval	NN	approval
may	MD	may
soon	RB	soon
provide	VB	provide
new	JJ	new
options	NNS	option
for	IN	for
prevention	NN	prevention
.	.	.
</s>
<s type="decl">
Gene	NN	Gene
therapy	NN	therapy
and	CC	and
the	DT	the
use	NN	use
of	IN	of
broadly	RB	broadly
neutralizing	VBG	neutralize
antibodies	NNS	antibody
are	VBP	be
also	RB	also
attracting	VBG	attract
a	DT	a
great	JJ	great
deal	NN	deal
of	IN	of
interest	NN	interest
as	IN	as
possible	JJ	possible
approaches	NNS	approach
to	TO	to
HIV/AIDS	NNP	HIV/AIDS
management	NN	management
.	.	.
</s>
</p>
<p>
<s type="decl">
Still	RB	still
,	,	,
different	JJ	different
challenges	NNS	challenge
remain	VBP	remain
in	IN	in
anti-HIV	NN	anti-HIV
drug	NN	drug
therapy/prophylaxis	NN	therapy/prophylaxis
,	,	,
and	CC	and
these	DT	these
include	VBP	include
the	DT	the
following	VBG	follow
,	,	,
among	IN	among
others	NNS	other
:	:	:
(	-LRB-	(
i	NNP	i
)	-RRB-	)
the	DT	the
onset	NN	onset
of	IN	of
severe	JJ	severe
adverse	NN	adverse
effects	NNS	effect
leading	VBG	lead
to	TO	to
the	DT	the
discontinuation	NN	discontinuation
or	CC	or
interruption	NN	interruption
of	IN	of
therapy	NN	therapy
or	CC	or
even	RB	even
prophylaxis	NN	prophylaxis
;	:	;
(	-LRB-	(
ii	NN	ii
)	-RRB-	)
sub-optimal	JJ	sub-optimal
biodistribution	NN	biodistribution
and	CC	and
pharmacokinetics	NNS	pharmacokinetics
,	,	,
particularly	RB	particularly
in	IN	in
reservoir	NN	reservoir
sites	NNS	site
or	CC	or
mucosae	NN	mucosae
involved	VBN	involve
in	IN	in
sexual	JJ	sexual
transmission	NN	transmission
;	:	;
(	-LRB-	(
iii	NN	iii
)	-RRB-	)
the	DT	the
occurrence	NN	occurrence
of	IN	of
viral	NN	viral
resistance	NN	resistance
;	:	;
(	-LRB-	(
iv	NN	iv
)	-RRB-	)
troublesome	JJ	troublesome
regimens	NNS	regimen
and/or	IN	and/or
drug	NN	drug
delivery	NN	delivery
routes	NNS	route
that	WDT	that
lead	VBP	lead
to	TO	to
poor	JJ	poor
adherence	NN	adherence
by	IN	by
patients/users	NNP	patients/user
;	:	;
(	-LRB-	(
v	NN	v
)	-RRB-	)
low	JJ	low
stability	NN	stability
and	CC	and
reduced	VBN	reduce
shelf-life	NN	shelf-life
of	IN	of
active	JJ	active
molecules	NNS	molecule
,	,	,
which	WDT	which
may	MD	may
be	VB	be
particularly	RB	particularly
challenging	VBG	challenge
in	IN	in
tropical	JJ	tropical
climates	NNS	climate
and	CC	and
low-resource	JJ	low-resource
regions	NNS	region
lacking	VBG	lack
adequate	JJ	adequate
refrigerated	VBN	refrigerate
distribution	NN	distribution
channels	NNS	channel
and	CC	and
storage	NN	storage
;	:	;
(	-LRB-	(
vi	NN	vi
)	-RRB-	)
lack	NN	lack
of	IN	of
suitable	JJ	suitable
dosage	NN	dosage
forms	NNS	form
for	IN	for
particular	JJ	particular
populations	NNS	population
(	-LRB-	(
e.	NNP	e.
g.	NN	g.
,	,	,
children	NNS	child
and	CC	and
women	NNS	woman
)	-RRB-	)
;	:	;
(	-LRB-	(
vii	NN	vii
)	-RRB-	)
costly	JJ	costly
drug	NN	drug
products	NNS	product
that	WDT	that
are	VBP	be
often	RB	often
inaccessible	JJ	inaccessible
to	TO	to
populations	NNS	population
in	IN	in
need	NN	need
of	IN	of
therapy/prophylaxis	NN	therapy/prophylaxis
;	:	;
and	CC	and
(	-LRB-	(
viii	NN	viii
)	-RRB-	)
social	JJ	social
and	CC	and
legal	JJ	legal
constraints	NNS	constraint
resulting	VBG	result
in	IN	in
poor	JJ	poor
access	NN	access
to	TO	to
and	CC	and
the	DT	the
discontinuation	NN	discontinuation
of	IN	of
anti-HIV	NN	anti-HIV
therapy/prophylaxis	NN	therapy/prophylaxis
.	.	.
</s>
<s type="sub">
The	DT	the
response	NN	response
from	IN	from
the	DT	the
scientific	JJ	scientific
community	NN	community
could	MD	could
not	RB	not
be	VB	be
more	RBR	more
affirmative	JJ	affirmative
,	,	,
and	CC	and
novel	NN	novel
ideas	NNS	idea
and	CC	and
concepts	NNS	concept
have	VBP	have
been	VBN	be
emerging	VBG	emerge
throughout	IN	throughout
the	DT	the
last	JJ	last
decade	NN	decade
or	CC	or
so	RB	so
.	.	.
</s>
<s type="decl">
More	RBR	more
important	JJ	important
,	,	,
innovative	JJ	innovative
products	NNS	product
are	VBP	be
now	RB	now
under	IN	under
development	NN	development
,	,	,
holding	VBG	hold
great	JJ	great
promise	NN	promise
for	IN	for
mitigating	VBG	mitigate
many	JJ	many
of	IN	of
the	DT	the
challenges	NNS	challenge
identified	VBN	identify
above	IN	above
.	.	.
</s>
</p>
<p>
<s type="decl">
This	DT	this
Special	NNP	Special
Issue	NNP	Issue
presents	VBZ	present
an	DT	an
exciting	JJ	excite
series	NN	series
of	IN	of
reviews	NNS	review
and	CC	and
original	JJ	original
research	NN	research
articles	NNS	article
from	IN	from
eminent	JJ	eminent
scientists	NNS	scientist
in	IN	in
academia	NN	academia
and	CC	and
different	JJ	different
nonprofit	JJ	nonprofit
organizations	NNS	organization
involved	VBN	involve
in	IN	in
the	DT	the
development	NN	development
of	IN	of
antiretroviral	JJ	antiretroviral
drug	NN	drug
products	NNS	product
,	,	,
focusing	VBG	focus
mainly	RB	mainly
on	IN	on
novel	NN	novel
strategies	NNS	strategy
for	IN	for
the	DT	the
formulation	NN	formulation
and	CC	and
delivery	NN	delivery
of	IN	of
anti-HIV	NN	anti-HIV
compounds	NNS	compound
.	.	.
</s>
<s type="decl">
Innovative	JJ	innovative
approaches	NNS	approach
towards	IN	towards
improved	VBN	improve
gene	NN	gene
therapy	NN	therapy
and	CC	and
immunotherapy	NN	immunotherapy
are	VBP	be
also	RB	also
addressed	VBN	address
.	.	.
</s>
<s type="decl">
The	DT	the
presented	VBN	present
reports	NNS	report
provide	VBP	provide
not	RB	not
only	RB	only
interesting	JJ	interesting
overviews	NNS	overview
and	CC	and
opinion	NN	opinion
on	IN	on
recent	JJ	recent
developments	NNS	development
in	IN	in
the	DT	the
broad	JJ	broad
field	NN	field
of	IN	of
antiretroviral	JJ	antiretroviral
therapy/prophylaxis	NN	therapy/prophylaxis
and	CC	and
drug	NN	drug
delivery	NN	delivery
,	,	,
but	CC	but
also	RB	also
describe	VB	describe
the	DT	the
development	NN	development
of	IN	of
new	JJ	new
products	NNS	product
that	WDT	that
are	VBP	be
currently	RB	currently
tracked	VBN	track
for	IN	for
clinical	JJ	clinical
testing	NN	testing
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
Special	NNP	Special
Issue	NNP	Issue
starts	VBZ	start
with	IN	with
an	DT	an
interesting	JJ	interesting
review	NN	review
by	IN	by
Tsukamoto	NNP	Tsukamoto
at	IN	at
Kindai	NNP	Kindai
University	NNP	University
,	,	,
Japan	NNP	Japan
,	,	,
on	IN	on
strategies	NNS	strategy
explored	VBN	explore
for	IN	for
curing	VBG	curing
HIV	NN	HIV
infection	NN	infection
using	VBG	use
a	DT	a
combination	NN	combination
of	IN	of
gene	NN	gene
therapy	NN	therapy
and	CC	and
host	VB	host
immunization	NN	immunization
.	.	.
</s>
<s type="decl">
In	IN	in
particular	JJ	particular
,	,	,
the	DT	the
author	NN	author
emphasizes	VBZ	emphasize
the	DT	the
possible	JJ	possible
role	NN	role
of	IN	of
anti-HIV	NN	anti-HIV
intracellular	JJ	intracellular
immunization	NN	immunization
using	VBG	use
gene	NN	gene
silencing	NN	silence
,	,	,
among	IN	among
other	JJ	other
approaches	NNS	approach
,	,	,
in	IN	in
the	DT	the
protection	NN	protection
of	IN	of
bone	NN	bo
marrow	NN	marrow
hematopoietic	JJ	hematopoietic
stem/progenitor	NN	stem/progenitor
cells	NNS	cell
.	.	.
</s>
<s type="decl">
Still	RB	still
in	IN	in
the	DT	the
same	JJ	same
field	NN	field
,	,	,
Düzgüneş	NNP	Düzgüneş
and	CC	and
Konopka	NNP	Konopka
at	IN	at
the	DT	the
University	NNP	University
of	IN	of
the	DT	the
Pacific	NNP	Pacific
,	,	,
USA	NNP	USA
,	,	,
contributed	VBD	contribute
a	DT	a
stimulating	VBG	stimulate
review	NN	review
on	IN	on
a	DT	a
potential	JJ	potential
strategy	NN	strategy
for	IN	for
the	DT	the
eradication	NN	eradication
of	IN	of
cellular	JJ	cellular
reservoirs	NNS	reservoir
of	IN	of
HIV	NNP	HIV
.	.	.
</s>
<s type="decl">
This	DT	this
thought-provoking	JJ	thought-provoking
piece	NN	piece
explores	VBZ	explore
how	WRB	how
such	PDT	such
an	DT	an
objective	NN	objective
could	MD	could
be	VB	be
achieved	VBN	achieve
by	IN	by
using	VBG	use
suicide	JJ	suicide
gene	NN	gene
therapy	NN	therapy
for	IN	for
killing	VBG	kill
HIV-infected	VBN	HIV-infected
cells	NNS	cell
,	,	,
excision	NN	excision
of	IN	of
chromosome-integrated	JJ	chromosome-integrated
viral	NN	viral
DNA	NN	DNA
,	,	,
and	CC	and
cytotoxic	NN	cytotoxic
liposomes	NNS	liposome
targeted	VBN	target
to	TO	to
latency-reversed	JJ	latency-reversed
HIV-infected	JJ	HIV-infected
cells	NNS	cell
.	.	.
</s>
</p>
</text>
